CCIA
ATXS

Campbell & Co Investment Adviser’s Astria Therapeutics ATXS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,202
Closed -$535K – 872
2023
Q1 		$535K Buy
+40,202
New +$544K 0.1% 397

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Campbell & Co Investment Adviser's ATXS Position: Q2 2023 in Review

Campbell & Co Investment Adviser sold out of Astria Therapeutics (ATXS) in Q2 2023, closing a stake of 40,202 shares — an estimated $535K sold.

Campbell & Co Investment Adviser first reported a position in ATXS in Q1 2023 and held it in 1 quarter. The position peaked at $535K in Q1 2023. 76 funds tracked by Wall St. Rank hold ATXS as of Q2 2023.

  • Campbell & Co Investment Adviser reported no remaining Astria Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 40,202 Astria Therapeutics shares in Q2 2023, an estimated $535K.
  • Campbell & Co Investment Adviser first reported a position in Astria Therapeutics in Q1 2023 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Astria Therapeutics position peaked at $535K in Q1 2023.
  • 76 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2023, filed 11 Aug 2023.